Published in Nat Rev Clin Oncol on June 05, 2012
Comparative effectiveness of minimally invasive vs open radical prostatectomy. JAMA (2009) 7.25
Intensity-modulated radiation therapy, proton therapy, or conformal radiation therapy and morbidity and disease control in localized prostate cancer. JAMA (2012) 5.90
Cost implications of the rapid adoption of newer technologies for treating prostate cancer. J Clin Oncol (2011) 4.60
Is proton beam therapy cost effective in the treatment of adenocarcinoma of the prostate? J Clin Oncol (2007) 2.96
Active surveillance for prostate cancer: progress and promise. J Clin Oncol (2011) 2.93
High-intensity focused ultrasound for prostate cancer: a systematic review. Clin Oncol (R Coll Radiol) (2010) 2.02
Re: editorial comment on focal therapy for localised unifocal and multifocal prostate cancer: a prospective development study (lancet oncol 2012; 13: 622-632). J Urol (2012) 1.15
Outcomes for radical prostatectomy: is it the singer, the song, or both? J Clin Oncol (2012) 1.14
Proton beam therapy and treatment for localized prostate cancer: if you build it, they will come. Arch Intern Med (2012) 0.82
Active surveillance for the management of prostate cancer in a contemporary cohort. Cancer (2008) 4.77
Active surveillance for prostate cancer: a systematic review of the literature. Eur Urol (2012) 4.24
Prediction of erectile function following treatment for prostate cancer. JAMA (2011) 3.92
Active surveillance for early-stage prostate cancer: review of the current literature. Cancer (2008) 3.18
Impact of age at diagnosis on prostate cancer treatment and survival. J Clin Oncol (2010) 2.89
Prognostic implications of an undetectable ultrasensitive prostate-specific antigen level after radical prostatectomy. Eur Urol (2009) 2.88
Renal cell cancer stage migration: analysis of the National Cancer Data Base. Cancer (2008) 2.83
Androgen deprivation therapy and cardiovascular risk. J Clin Oncol (2011) 2.55
Management of biochemical recurrence after primary treatment of prostate cancer: a systematic review of the literature. Eur Urol (2013) 2.46
A simple schema for informed decision making about prostate cancer screening. Ann Intern Med (2014) 2.12
Changes in prostate cancer grade on serial biopsy in men undergoing active surveillance. J Clin Oncol (2011) 2.08
Time trends and characteristics of men choosing watchful waiting for initial treatment of localized prostate cancer: results from CaPSURE. J Urol (2003) 1.93
How does robot-assisted radical prostatectomy (RARP) compare with open surgery in men with high-risk prostate cancer? BJU Int (2013) 1.61
Patient demographics, quality of life, and disease features of men with newly diagnosed prostate cancer: trends in the PSA era. Urology (2013) 1.59
Postoperative statin use and risk of biochemical recurrence following radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database. BJU Int (2014) 1.58
The quantitative Gleason score improves prostate cancer risk assessment. Cancer (2012) 1.57
Impact of obesity on prostate cancer recurrence after radical prostatectomy: data from CaPSURE. Urology (2005) 1.57
The impact of pathologic staging on the long-term oncologic outcomes of patients with clinically high-risk prostate cancer. Cancer (2014) 1.51
Use of social media in urology: data from the American Urological Association (AUA). BJU Int (2014) 1.43
Proximal bulbar periurethral abscess. Int Braz J Urol (2013) 1.40
Impact of national guidelines on brachytherapy monotherapy practice patterns for prostate cancer. Cancer (2013) 1.39
Ability of 2 pretreatment risk assessment methods to predict prostate cancer recurrence after radical prostatectomy: data from CaPSURE. J Urol (2005) 1.37
Geographic distribution of urologists throughout the United States using a county level approach. J Urol (2008) 1.35
Prostate cancer mortality following active surveillance versus immediate radical prostatectomy. Clin Cancer Res (2012) 1.25
Mapping tumor epitope space by direct selection of single-chain Fv antibody libraries on prostate cancer cells. Cancer Res (2004) 1.25
Expected population impacts of discontinued prostate-specific antigen screening. Cancer (2014) 1.24
The relationship between prostate specific antigen change and biopsy progression in patients on active surveillance for prostate cancer. J Urol (2011) 1.23
Outcomes for radical prostatectomy: is it the singer, the song, or both? J Clin Oncol (2012) 1.14
Urologist density and county-level urologic cancer mortality. J Clin Oncol (2010) 1.10
Seventh Joint Meeting of K-J-CaP and CaPSURE: extending the global initiative to improve prostate cancer management. Prostate Int (2014) 1.08
Adequacy of a single 24-hour urine collection for metabolic evaluation of recurrent nephrolithiasis. J Urol (2010) 1.08
Differences in clinical characteristics and disease-free survival for Latino, African American, and non-Latino white men with localized prostate cancer: data from CaPSURE. Cancer (2006) 1.07
Obesity and prostate cancer clinical risk factors at presentation: data from CaPSURE. J Urol (2005) 1.00
The impact of obesity on health related quality of life before and after radical prostatectomy (data from CaPSURE). J Urol (2005) 1.00
Health related quality of life in patients treated with multimodal therapy for prostate cancer. J Urol (2008) 0.99
Electronic patient self-assessment and management (SAM): a novel framework for cancer survivorship. BMC Med Inform Decis Mak (2010) 0.98
Laparoscopic management of peripelvic renal cysts: University of California, San Francisco, experience and review of literature. Urology (2005) 0.98
Prostate specific antigen screening for prostate cancer: knowledge of, attitudes towards, and utilization among primary care physicians. Urol Oncol (2010) 0.97
Inaccuracies in assignment of clinical stage for localized prostate cancer. Cancer (2010) 0.96
The epidemiology of high-risk prostate cancer. Curr Opin Urol (2013) 0.93
A longitudinal study of anxiety, depression and distress as predictors of sexual and urinary quality of life in men with prostate cancer. BJU Int (2013) 0.93
Who is the average patient presenting with prostate cancer? Urology (2005) 0.93
Diagnostic associations of gene expression signatures in prostate cancer tissue. Curr Opin Urol (2015) 0.92
The example of CaPSURE: lessons learned from a national disease registry. World J Urol (2011) 0.92
Patients with primary hyperparathyroidism--why do some form stones? J Urol (2009) 0.92
Fifth Joint Meeting of J-CaP and CaPSURE: advancing the global understanding of prostate cancer and its management. Jpn J Clin Oncol (2012) 0.91
Minimal impact of clinical stage on prostate cancer prognosis among contemporary patients with clinically localized disease. J Urol (2010) 0.91
Temporal trends and predictors of salvage cancer treatment after failure following radical prostatectomy or radiation therapy: an analysis from the CaPSURE registry. Cancer (2013) 0.91
The independent value of tumour volume in a contemporary cohort of men treated with radical prostatectomy for clinically localized disease. BJU Int (2009) 0.91
Serum prostate-specific antigen for the early detection of prostate cancer: always, never, or only sometimes? J Clin Oncol (2010) 0.88
Changes in specific domains of sexual function and sexual bother after radical prostatectomy. BJU Int (2010) 0.88
Prostate cancer risk assessment: choosing the sharpest tool in the shed. Cancer (2008) 0.87
Prostate-cancer screening. N Engl J Med (2009) 0.86
Are age-based criteria the best way to determine eligibility for prostate cancer screening? Ann Intern Med (2009) 0.86
Contemporary prevalence of pretreatment urinary, sexual, hormonal, and bowel dysfunction: Defining the population at risk for harms of prostate cancer treatment. Cancer (2014) 0.86
In vivo tumor grading of prostate cancer using quantitative 111In-capromab pendetide SPECT/CT. J Nucl Med (2009) 0.84
Gender differences in subcutaneous and perirenal fat distribution. Surg Radiol Anat (2010) 0.83
Meaningful end points and outcomes in men on active surveillance for early-stage prostate cancer. Curr Opin Urol (2014) 0.83
Role of active surveillance in the management of localized prostate cancer. J Natl Cancer Inst Monogr (2012) 0.83
Impact of the United States Preventive Services Task Force 'D' recommendation on prostate cancer screening and staging. Curr Opin Urol (2017) 0.83
Proton beam therapy and treatment for localized prostate cancer: if you build it, they will come. Arch Intern Med (2012) 0.82
To predict the future, consider the present as well as the past. Eur Urol (2012) 0.82
Reflex ImmunoCyt testing for the diagnosis of bladder cancer in patients with atypical urine cytology. Eur Urol (2012) 0.81
Factors associated with downgrading in patients with high grade prostate cancer. Urol Oncol (2011) 0.81
Re-examining racial disparities in prostate cancer outcomes. J Clin Oncol (2013) 0.80
Sixth joint meeting of J-CaP and CaPSURE--a multinational perspective on prostate cancer management and patient outcomes. Jpn J Clin Oncol (2013) 0.80
Disproportionate presentation of high risk prostate cancer in a safety net health system. J Urol (2010) 0.79
Risk-based prostate cancer screening: who and how? Curr Urol Rep (2013) 0.79
Adverse effects of androgen deprivation and the limits of national tumor registries. Eur Urol (2011) 0.78
Among potent men post radical prostatectomy, does the need for phosphodiesterase inhibitors have an impact on sexual bother scores? BJU Int (2011) 0.77
High-risk nonmuscle invasive bladder cancer: definition and epidemiology. Curr Opin Urol (2012) 0.77
Will biomarkers save prostate cancer screening? Eur Urol (2012) 0.77
Thwarting high-risk prostate cancer: the right treatments for the right patients. Eur Urol (2012) 0.77
Divorcing diagnosis from treatment: contemporary management of low-risk prostate cancer. Korean J Urol (2013) 0.76
Editorial comment. Urology (2011) 0.75
Early detection of prostate cancer: more information, more clarity. Eur Urol (2012) 0.75
Factors associated with treatment received by men diagnosed with prostate cancer in queensland, australia. BJU Int (2012) 0.75
Is clinical stage T2c prostate cancer an intermediate- or high-risk disease? Cancer (2014) 0.75
Editorial comment. Urology (2012) 0.75
Proton therapy websites: information anarchy creates confusion. BJU Int (2015) 0.75
Long-term follow-up of International Prostate Symptom Score (IPSS) in men following prostate brachytherapy. World J Urol (2013) 0.75
Histologic Grading of Prostatic Adenocarcinoma Can Be Further Optimized: Analysis of the Relative Prognostic Strength of Individual Architectural Patterns in 1275 Patients From the Canary Retrospective Cohort. Am J Surg Pathol (2016) 0.75
Implementation of PSA-based active surveillance in prostate cancer. Biomark Med (2014) 0.75
Urinary citrate levels do not correlate with urinary pH in patients with urinary stone formation. Urology (2007) 0.75